Annexon Stock Forum

$Annexon (ANNX.US)$
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
Annexon (ANNX) announced positive topline results from a real-world evidence study comparing ANX005 treatment to IVIg/PE for Guillain-Barré Syndrome (GBS). The study matched 79 ANX005-treated patients from Phase 3 trials with 79 real-wo...

$Annexon (ANNX.US)$ Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
4 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in Interna...

$Annexon (ANNX.US)$
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Annexon presented new Phase 2 datafor ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology 2024 meeting. The study showed enhanced vision protection and greater preservation of central photoreceptor cells in patients with less advanced disease. Ke...

$Annexon (ANNX.US)$ Looking for this soon.
((((((. ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024 )))))

$Annexon (ANNX.US)$ Key Anticipated Milestones for Flagship Programs
*ANX005 in GBS: Initial topline data from RWE comparability protocol with IGOS now expected by year-end 2024 to support a planned BLA submission in the first half of 2025
*ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024

$Annexon (ANNX.US)$
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atroph...

$Annexon (ANNX.US)$ Did anyone remember to be watching for this? I told Y’all on the 18th to be looking! Hehehe

$Annexon (ANNX.US)$ Reuters· 5 mins ago
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting

$Annexon (ANNX.US)$
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
Significant improvements were noted in primary and mult...

$Annexon (ANNX.US)$ Annexon to Present Significant Phase 3 Results of ANX005 in Guillain-Barré Syndrome at PNS Annual Meeting; Potential to Be First Targeted Therapy for GBS! June 22-25,  2024